Clsi 2013 PDF
2/13/2013 jhindler clsi update 2013 1 What’s New in the 2013 CLSI Standards for Antimicrobial Susceptibility Testing (AST) ? Janet A. Hindler, MCLS MT(ASCP)
8/28/2012 jhindler CLSI M100-S22 Update 1 1 Update on the 2012-2013 CLSI Standards for Antimicrobial Susceptibility Testing: What’s New with the
3 CLSI AST Standards – January 2013 M100-S23 Tables (2013)* M02-A11 Disk Diffusion Method (2012)^ M07-A9 MIC Method (2012)^
CLSI M100-S23 January 2013 Major changes… Salmonella - more on fluoroquinolone breakpoints (BPs) Staphylococcus - - Eliminate oxacillin disk test for S.
Janet Kliethermes . NSH Representative to the Clinical Lab Standards Institute (CLSI) Annual Report . The Clinical and Laboratory Standards Institute (CLSI) has organized a new committee
Nelesh Govender, NICD 2013/03/08 SASCM meeting, ProteaHotel ORT 1 Candida species: Antifungal susceptibility testing in 2013 ... *CLSI M27-S4 2013 Case • Repeat valve replacement and patient changed to caspofungin • Patient died due to sepsis-related
M5036-1 Giles Scientific Inc. P.O. Box 4306 Santa Barbara, CA 93140 USA Phone: (805) 963-3876 Fax: (805) 963-7768 Email: [email protected] www.biomic.com
March 7, 2013 Learning Objectives • Review the methods by which CLSI sets and revises susceptibility breakpoints. • List reasons behind CLSI breakpoint revisions. • Discuss recent CLSI breakpoint revisions and their impact on laboratory reporting.
What’s New in the 2013 CLSI Standards for Antimicrobial Susceptibility Testing (AST) ? Janet A. Hindler, MCLS MT(ASCP) UCLA Health System [email protected]
Dear customer, In order to better classify our library of documents, the Clinical and Laboratory Standards Institute (CLSI) has expanded and color coded its document categories.
1 CLSI Rationale Document – Doxycycline and Tetracycline Breakpoints for Streptococcus pneumoniae: 2013 Background/Introduction: Doxycycline represents an alternative oral agent for ambulatory patients (especially those that are
Clinical and Laboratory Standards Institute Setting the standard for quality in clinical laboratory testing around the world. The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together
Active Membership (As of 1 August 2013) Industry and Large Commercial Laboratories Abbott Laboratories (IL) Abbott Point of Care Inc. (NJ) AdvaMed (DC)
Related searches for clsi breakpoints 2013 cefepime Consequences of revised CLSI and EUCAST guidelines for ... www.ncbi.nlm.nih.gov/pubmed/23633681 Significant differences in the susceptibility rates of important cephalosporins such as
April 18 th, 2013- 1:00 PM EST In October 2011, CLSI published EP 23 Laboratory Quality Control Based on Risk Assessment. In the first five months more than 400 copies of this document were sold. CMS has stated that EP23 will be the approved guidance for developing CLIA acceptable
• CLSI is Secretariat for ISO Technical Committee (TC) 212 “Clinical laboratory testing and in vitro diagnostic test ... • Projected need for 710 000 technologists by 2013 33. External Factors • Significant growth in number of waived tests
jhindler APHL belt 2013 2 CLSI M45-A2 Guideline “Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious
CLSI 2013 Annual Leadership Conference Arlington, Va. www.clsi.org/education-programs/symposiums mar 13 – 16 Mayo Medical Laboratories TransFuse 2013: Transformative Fusion of Innovative Blood Management Technologies ...
2) Upon using new Streptococcus AST cards containing Erythromycin, and if you are using the CLSI Interpretation Standard in the VITEK 2 Systems (V2S) software versions 05.03
CLSI Guidelines on Newborn Screening for Severe Combined Immunodeficiency (SCID) Lisa Kobrynski, MD, MPH Marcus Professor of Immunology Department of Pediatrics
clsi 2013 m100 s23 clsi m100-s23 january ... (2013) 1 m02-a11 disk diffusion method (2012) 2 m07-a9 mic method (2012) 590-601-13-3SlidesPerPage.pdf Read Now ... Antimicrobial Susceptibility Testing (AST) of Bacteria ...
28 Abstract 29 30 Multi drug resistance (MDR) rates of Gram-negative rods were analysed comparing 31 CLSI 2009 and EUCAST 2011 antibiotic susceptibility testing guidelines.
*Adapted in part from CLSI document M100-S23 (M02-A11) : “Disc di ffusion supplemental tablesʼʼ Performance standards for antimicrobial susceptibility testing.
August 2013 Carbapenem-Resistant Enterobacteriaceae (CRE) Notification Protocol Division of Infectious Disease Epidemiology ... (CLSI) guidelines. 2. Assure that your laboratory is immediately reporting carbapenem resistant test results to you.
Document Title CLSI Product Code Vol No Replaces Approval Date STATUS P erformance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacterial isolated from Animals VET01-A4 July 2013 Fourth Edition – This document provides the currently recommended techniques for
Reference: CLSI Document H21-A (Collection,Transport, and Processing of Blood Specimens for Testing ... 2013 Identified how Lab Central Connect will be used in your survey Listed the available resources for your organization .
Relevant CLSI Reference Materials1 C28-A3c Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved
were accompanied by signiﬁcantly higher cephalosporin zone diameter clinical breakpoints (CBPs) in EUCAST 2013 compared with CLSI 2009 and, in part, EUCAST 2010.
126.96.36.199 Rev. 7 2013-Jul-03 CLSI Magnet Power Supply Specification Page 4 The circuit breaker on the power supply shall have an interrupting capacity of at
Update on CLSI Guidelines: NBS06-A May 2010 • SCID added to Recommended Uniform Screening Panel August 2011 • CLSI convened DDC in Atlanta
Clinical and Laboratory Standards Institute Advancing Quality in Healthcare Testing The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) is an international, interdisciplinary,
P/N 60-00880-0 Page 7 of 14 11. Click in Source column to edit from FDA to CLSI reference. 12. Click Save. This action is required after each breakpoint modification is complete.
February 2013 QMS02-A6 Quality Management System: Development and Management of Laboratory Documents; Approved Guideline—Sixth Edition ... The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings
Supplement (January 2013). The current CLSI documents for the performance of antimicrobial susceptibility testing by disk diffusion and the quality control accuracy limits are M2-A11; Performance Standards for Antimicrobial
What dosages are most prescribed? CLSI at 2013-10-17 PK-PD-Breakpoint AIDAC 12 Data courtesy of Vikas Gupta, Pharm.D., BCPS, Director, CareFusion MedMined™ services
Clinicaland Laboratory Standards Institute (CLSI) guidelines: MIC tests should be performed to determine the susceptibilityof all isolates of staphyloccito vancomycin.The disk test does not differentiate vancomycin ...
CLSI Documents Referenced to The Joint Commission Laboratory Accreditation Standards Chapters Updated July 2013 950 West Valley Road, Suite 2500, Wayne, PA 19087 | P: 610.688.0100 | Toll Free (US): 877.447.1888 | F: 610.688.0700 | E: firstname.lastname@example.org
4/3/2013 3 Criteria for isolates if laboratory is using “newer” CLSI breakpoints Enterobacteriaceae reported out as I or R by automated instrument
CLIA Update 2013 Judith Yost, M.A., M.T.(ASCP) Director . Division of Laboratory Services . CLIA. CLIA Topics For Discussion ... • CLSI convened the well-attended ‘QC for the Future’ meeting in 2005 • Sponsored by accrediting orgs., industry,
b. Serogroup comprised of eight and 128 isolates of 19F and 19A, respectively. c. Criteria as published by the CLSI (2013) for 'penicillin parenteral (non-meningitis)'.
Because CLSI 2013  and EUCAST 2013  still suggest different brea3 k-points, discrepancies due to the guidelines adopted by clinicians could lead to an important impact on the selec-tion of the first-line antibiotic to be used in bloodstream
8 ORDER TODAY: Toll Free (US): 877.447.1888 | www.clsi.org | email@example.com 2013 Catalog Table of Contents Document and Product Listings by Specialty Area
Special Reviewers M29 (Draft 2), Protection of Laboratory Workers From Occupationally Acquired Infections; Draft Guideline—Fourth Edition 8 July 2013 – 22 August 2013
•2013 CLSI document M100-S23 is on order for MI labs . Background ... carbapenemase but still test as “S” Carbapenem breakpoints were revised by CLSI in June 2010
2013 Clinical Microbiology Department of Pathology & Laboratory Medicine. 51 Antimicrobial Susceptibility Summary Clinical Microbiology ... Institute (CLSI) guidelines. When deciding whether the interpretation is meaningful, one should consider the
New CLSI guidelines for Quality System in the Molecular Genetics Laboratory - MM20 APOGÉE-Net/CanGèneTest Network Montréal, January 28th 2013
S23 (2013) and quality control (QC) was performed using E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853. All QC results were within acceptable ranges as published in CLSI (M100- S23, 2013) documents. Screening for β-lactamases.
Reflects change in CLSI recommended Order of Draw (H3-A5, Vol 23, No 32, 8.10.2) Created Date: 1/18/2010 9:57:35 AM ...
References . Methods . Revised Abstract Methods 30. Printed by. Tier 2 Quality Control Study (CLSI M23-A3) for Microtiter Broth and Disk Diffusion Testing of Eravacycline (TP -434)
concentrations (MICs) were interpreted using CLSI M100-S23 (2013) breakpoints (1). Fosfomycin-intermediate and -resistant isolates were each retested to confirm their phenotype. a